Communication from the ISTH SSC Subcommittee on Women’s Health Issues in Thrombosis and Haemostasis: A Survey on Anticoagulation for Mechanical Heart Valves in Pregnancy [Текст] / I. Malhame [et al.] // Український журнал Перинатологія і Педіатрія. - 2021. - № 3. - С. 83-91 MeSH-головна: ТРОМБОЗ -- THROMBOSIS (лекарственная терапия, патофизиология) АНТИКОАГУЛЯНТЫ -- ANTICOAGULANTS (терапевтическое применение) ЖЕНЩИНЫ БЕРЕМЕННЫЕ -- PREGNANT WOMEN КЛИНИЧЕСКИЕ ПРОТОКОЛЫ -- CLINICAL PROTOCOLS Анотація: Patients with mechanical heart valves (MHV)s require life-long anticoagulation to prevent thromboembolic complications (TECs). Women with MHVs in pregnancy experience an increased risk of severe maternal morbidity and mortality from both thrombotic and bleeding complications. A large international registry of pregnancies with MHVs revealed that valve thrombosis and maternal mortality occurred in 4.7% and 1.4% of women, respectively, and hemorrhage complicated 23% of pregnancies.1 Of importance, only 58% of women with MHVs were free from serious adverse events during pregnancy compared with 79% of women with bioprosthetic valves and 78% of women with cardiac disease and no prosthetic valves Дод.точки доступу: Malhame, I. Othman, M. Casais, P. D’Souza, R. Wald, R. M. Silversides, C. K. Sermer, M. Shehata, N. Вільних прим. немає